RxDoctor Payments Data

Shahnawaz Meer, MD

Psychiatry · Lakewood, NYNPI 1922261080

Payments from drug & device makers

$132,407in general payments, 2019–2025

Across 263 payments — averaging $503.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$75K
  • AbbVie$40K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Supernus Pharmaceuticals, Inc.$8K
  • Otsuka America Pharmaceutical, Inc.$197
  • Sunovion Pharmaceuticals Inc.$145
  • plus $641 from 11 others

What the payments were for

  • Consulting fees$10,8158%
  • Speaking & faculty fees$102,02577%
  • Travel & lodging$12,72110%
  • Food & beverage$6,7635%
  • Education$830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,407 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$27,640
Medicare patients
72
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl75$108,320
RexultiBrexpiprazole66$104,355
LybalviOlanzapine/Samidorphan Malate35$55,995
Abilify MaintenaAripiprazole18$49,136
AristadaAripiprazole Lauroxil12$42,981
PerserisRisperidone12$40,491
Lurasidone Hcl66$39,600
CaplytaLumateperone Tosylate14$25,852
Aripiprazole283$10,193
TrintellixVortioxetine Hydrobromide15$9,945
Divalproex Sodium ErDivalproex Sodium118$6,982
Fluvoxamine Maleate ErFluvoxamine Maleate15$5,701
Lisdexamfetamine Dimesylate15$5,204
Methylphenidate ErMethylphenidate Hcl41$5,032
Vilazodone Hcl36$4,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$197$153,49184 claims
AbbVieVraylar$39,683$108,32075 claims
Alkermes, Inc.Lybalvi, Aristada$75,236$98,97647 claims
Indivior Inc.Perseris$20$40,49112 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$103$25,85214 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$61$9,94515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Lakewood

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →